GC WellBeing Corporation (234690) Fair Value & Analysis
Healthcare · KR · Market cap 137B KRW
Fair value as of: Jul 20, 2026
From 15 valuation models · updated 21 days ago
Share price +11.9% over the past month.
Below-average quality, and screening another 13% overvalued on our models.
What matters now
- Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
- Our model range runs from 5,923 KRW (bear) to 9,872 KRW (bull), base 7,898 KRW. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 47/100 (below-average quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 5,685 KRW – 15,100 KRW · fair‑value band 5,923 KRW – 9,872 KRW · the 9,120 KRW price screens above the 7,898 KRW fair value. Dashed = 300-day average. As of Jul 20, 2026.
Analysis
GC WellBeing Corporation (234690) currently trades at 9,120 KRW, while our model-based Fair Value estimate is 7,898 KRW, implying the stock looks roughly 13.4% overvalued today. The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, GC WellBeing Corporation generated revenue of 179B KRW at a net margin of 1.0%. Revenue grew 41.3% year over year. It earns a return on equity of 1.7%. Net debt stands at 62.1B KRW. Fundamentals as of Jul 20, 2026
Our scenario range runs from 5,923 KRW (bear case) to 9,872 KRW (bull case); at 9,120 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high and 22% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -13%, 234690 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: DCF Models (17,026 KRW) versus Asset-Based (4,255 KRW). Highest evidence: Residual Income (76).
Notify me when 234690 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 33
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
GC WellBeing Corporation provides personalized nutrition injections in South Korea. The company offers health supplements and food; prescription drugs; and aesthetics, as well as nutritional injections, including vitamins and antioxidants.
Full company description
GC WellBeing Corporation provides personalized nutrition injections in South Korea. The company offers health supplements and food; prescription drugs; and aesthetics, as well as nutritional injections, including vitamins and antioxidants. The company was formerly known as GREEN CROSS WellBeing Corporation and changed its name to GC WellBeing Corporation in April 2026. The company was founded in 2004 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
GC WellBeing Corporation reported revenue of 165B KRW in FY2025 versus 91.0B KRW in FY2021, a compound +16.0%/yr. Reported net income was 10.0B KRW in FY2025, compounding +10.5%/yr from FY2021.
234690 screens 13% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare GC WellBeing Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is GC WellBeing Corporation (234690) overvalued or undervalued?
What is the fair value of 234690?
What is the quality score of 234690?
What is the revenue of GC WellBeing Corporation (234690)?
What is the net profit margin of 234690?
Does GC WellBeing Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track GC WellBeing Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.